Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LTRN with free AI briefings, catalyst countdowns, and dilution alerts.

LTRN · Lantern Pharma Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.4M Cash on Hand
6.6mo Cash Runway
Follow LTRN by email Get an email when LTRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LTRN, unsubscribe in one click. Privacy

📣 What LTRN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Irofulven Metastatic Castration-Resistant Prostate Cancer Patients Phase 2 · NCT03643107 Completed
Zirdafulven (LP-184) Advanced Solid Tumor Phase 1/2 · NCT05933265 Active not recruiting
Nivolumab & Ipilimumab Advanced Solid Tumor Phase 1/2 · NCT05933265 Active not recruiting
LP-284 Relapsed or Refractory Lymphomas Phase 1 · NCT06132503 Recruiting

Also used in these trials (approved or third-party drugs, not LTRN's own candidates): Dimesna (BNP7787), Cisplatin, Carboplatin, Olaparib, Pemetrexed Disodium.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LTRN holds $7.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.4M/quarter from operations, an estimated runway of 6.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 67 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LTRN files for a raise →

👥 Who Owns LTRN

Insiders 7.6% Other 5%+ holders 23.6% Institutions (46 holders) 17.6% Public and other holders 51.2%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13G, 5%+) 1,542,681 12.07% 2026-09-30
Leslie W. Kreis
10% owner
Includes shares also reported by Aaron G.L. Fletcher, counted once
Insider 1,075,952 8.42% 2025-06-13
CAVU MANAGEMENT, LP 5%+ holder (13D) 1,075,952 8.42% 2025-06-12
Thomas A. Satterfield, Jr. 5%+ holder (13G) 975,000 7.63% 2026-06-30
BIOS CAPITAL MANAGEMENT, LP 5%+ holder (13D) 960,026 7.51% 2026-02-20
Aaron G.L. Fletcher
10% owner
Insider 834,752 6.53% 2026-04-16
D Jeffrey Keyser
Director · +94,723 options
Insider 94,303 0.74% 2026-05-12
Lee Troy Schalop
Director · +72,004 options
Insider 48,544 0.38% 2026-05-12

Share count 12,784,146 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LTRN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LTRN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.